Magnetic Shunt Trial Solves a 60-Year NPH Mystery

Dr. James Whitfield

It is, uh, it is honestly one of the oldest, most persistent head-scratchers in modern neurology. We have been drilling holes in the skulls of elderly patients since, oh, nineteen sixty five, to implant these plastic tubes, these, these ventriculoperitoneal shunts, all to drain spinal fluid for a condition we call iNPH. Idiopathic normal pressure hydrocephalus.

Dr. Elena Rodriguez

Right, the classic triad. I mean, every medical student learns the mnemonic, right? Wobbly, wacky, and wet. Walking issues, cognitive decline, and urinary incontinence. It is, uh, it is Salomon Hakim and Raymond Adams who first put that picture together sixty years ago.

Dr. James Whitfield

Exactly. Wobbly, wacky, and wet. But, Elena, here is the dirty little secret we have carried for decades. We never actually had high quality, placebo controlled trial evidence showing that the shunt itself was doing the work. I mean, think about it. How do you do a placebo controlled trial for invasive neurosurgery? Do you do a sham surgery? Do you, do you drill a fake hole in someone's skull? You, you ethically just cannot do that.

Dr. Elena Rodriguez

No, absolutely not. No institutional review board on earth is going to let you do a sham craniotomy. It is, it is a massive ethical barrier. Which is why this new study, the, the PENS trial, which was published in the New England Journal of Medicine on September sixteenth, two thousand twenty five, is just so brilliant. Dr. Mark Luciano and his team at Johns Hopkins found this incredibly elegant way around the placebo problem without doing fake surgeries.

Dr. James Whitfield

It is a beautiful piece of study design. They took ninety nine patients who had already shown they reacted well to a temporary drain, like a spinal tap, which is our usual way of guessing who will benefit from a permanent shunt. But then, they did something truly wild with the actual hardware.

Dr. Elena Rodriguez

Yes! They used this specific adjustable valve, the, uh, the Codman Certas Plus. Everyone in the trial, all ninety nine patients, got the real surgery. They all had the shunt implanted. But here is the trick. Once the surgery was done, the researchers used an external magnetic programmer, just holding it against the patient's scalp, to change the valve setting. Half the patients had their shunts set to active drainage, at one hundred and ten millimeters of water pressure. But the other half, the placebo group, had their shunts turned essentially off.

Dr. James Whitfield

Set to, what, over four hundred millimeters of water pressure, right?

Dr. Elena Rodriguez

Exactly. Over four hundred. Which is so high that under normal physiological pressures, no cerebrospinal fluid can actually flow through it. It is a noninvasive, magnetic off switch. The patients did not know if their shunt was open or closed. The doctors evaluating them did not know. It was a true double blind, surgical placebo trial.

Dr. James Whitfield

And they only kept that off switch on for three months, which was the ethical sweet spot. Three months is, uh, it is long enough to see if there is a real difference in how they walk, but short enough that you are not permanently withholding a potentially life changing treatment from the placebo group. After three months, everyone in the placebo group had their valves magnetically turned on to the active setting.

Dr. Elena Rodriguez

It is just a beautiful way to solve a sixty year old ethical deadlock. But, man, the results, they really shake up what we thought we knew about that classic triad.

Dr. James Whitfield

They really, really do. Let's look at the wobbly part first, because that was the absolute home run. At three months, the patients with the active, open shunts saw their walking speed, their gait velocity, increase by a mean of zero point two three meters per second. The placebo group? Virtually nothing. Zero point zero three meters per second. That is a treatment difference of zero point two one meters per second. And the P value was less than zero point zero zero one. That is incredibly robust. Their balance, measured by the Tinetti scale, also saw a major improvement.

Dr. Elena Rodriguez

Wow. Zero point two one meters per second difference in walking speed is not just statistically significant, James. That is a massive, noticeable difference in daily life. That is the difference between crossing the street safely before the light changes and getting stuck in the middle. But, okay, what about the other two parts of the triad? The, uh, the wacky and the wet? The dementia and the bladder control?

Dr. James Whitfield

Well, that is where the clinical dogma kind of took a beating. There was no statistically significant difference between the active shunt group and the placebo group when it came to cognitive function. They used the Montreal Cognitive Assessment, the MoCA, and the active group improved by one point three points, while the placebo group improved by zero point three. Statistically, that is a wash. And the urinary incontinence, measured by the Overactive Bladder Questionnaire? Also no real difference. None.

Dr. Elena Rodriguez

Wait, seriously? So the cognitive decline and the bladder issues did not actually get better from the physical fluid drainage in those first three months? It was only the walking?

Dr. James Whitfield

Exactly. In the short term, at least, a VP shunt is essentially a mobility intervention. It is not a cure for the cognitive decline or the bladder issues. And that is a huge deal for how we talk to patients, because, as you know, these shunts are not free rides. They carry some really serious risks.

Dr. Elena Rodriguez

Oh, absolutely. I mean, if you are actively draining fluid out of the brain, you are lowering the pressure in there. If you drain too much, the brain can actually pull away from the skull, which stretches and tears those delicate bridging veins. And in the PENS trial, a striking twelve percent of the active shunt group suffered subdural bleeding. Twelve percent! Compared to only two percent in the placebo group. And fifty nine percent of the active group got those awful, positional, low pressure headaches, compared to twenty eight percent in the placebo group.

Dr. James Whitfield

But then, look at the flip side. The placebo group, because their balance did not improve, had nearly double the rate of falls. Forty six percent of them fell during those three months, compared to only twenty four point five percent of the active group.

Dr. Elena Rodriguez

That is a incredibly tough trade off. If I am sitting down with an eighty year old patient and their family, the conversation completely changes now. I can no longer say, let's put this shunt in to help with their memory and their bladder, and maybe it will help them walk. I have to say, this is a targeted, high risk mobility aid. It might keep you from falling, but there is a twelve percent chance of bleeding in your brain, and it probably won't fix your memory.

Dr. James Whitfield

Exactly. It completely redefines the clinical bedside conversation. It forces us to be much more precise, and frankly, much more cautious. It is no longer about curing wacky and wet. It is about weighing a very real, twelve percent risk of subdural hematoma against the profound, life changing desire to just walk without falling down. It is a tough choice, but at least now, thanks to this trial, we finally have the real, unbiased numbers to guide it.

Dr. Elena Rodriguez

Yeah, no more guessing. Well, that is it for us today. Talk to you next time, James.

Dr. James Whitfield

Sounds good, Elena. Talk soon.